Printer Friendly

TELIOS PHARMACEUTICALS FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING

 TELIOS PHARMACEUTICALS FILES REGISTRATION STATEMENT
 FOR INITIAL PUBLIC OFFERING
 SAN DIEGO, Feb. 10 /PRNewswire/ -- Telios Pharmaceuticals Inc. (the "company") announced today that it filed a registration statement with the Securities and Exchange Commission for the public offering of 3 million shares of its common stock, all for the company's account, 2.4 million shares of which will be offered in the United States and Canada by an underwriting group managed by Morgan Stanley & Co. Inc. and Hambrecht & Quist Inc. and 600,000 shares of which will be offered outside of the United States and Canada by an underwriting group managed by Morgan Stanley International, Hambrecht & Quist Inc. and Deutsche Bank Aktiengesellschaft. The underwriters anticipate that the per share price for the offering will be $10-$12. The company currently anticipates that it will use the net proceeds of the offering for research and development, including preclinical and clinical testing, manufacture of compounds, facilities expansion and other general corporate purposes.
 Telios was founded in 1987 to develop an important new class of therapeutic products based upon pioneering research into the role of the extracellular matrix, a meshwork of proteins and other compounds that surrounds most cells in the body. The company is applying its proprietary technology to develop products for the treatment of severe and chronic dermal wounds, ophthalmic wounds, fibrotic disease (such as certain kidney diseases, liver cirrhosis and acute respiratory distress syndrome), cardiovascular disease and osteoporosis.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A copy of the preliminary prospectus may be obtained from the offices of Morgan Stanley & Co. Inc., New York, New York or Hambrecht & Quist Inc., San Francisco, Calif.
 -0- 2/10/92 R
 /CONTACT: Audrey L. Dickason, director of corporate development, or David Duncan, Jr., VP-finance, of Telios Pharmaceuticals, 619-597-6109/ CO: Telios Pharmaceuticals, Inc. ST: California IN: MTC SU: OFR


AL -- SD002 -- 8677 02/11/92 09:30 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 11, 1992
Words:402
Previous Article:SCOTT SMITH NAMED CHAIRMAN OF MANNINGTON MILLS
Next Article:BARRISTER REPORTS THIRD QUARTER RESULTS FOR FISCAL YEAR 1992
Topics:


Related Articles
TELIOS PHARMACEUTICALS FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING
TELIOS PHARMACEUTICALS INC. SELLS 2.5 MILLION SHARES OF COMMON STOCK IN INITIAL PUBLIC OFFERING
WATSON PHARMACEUTICALS ANNOUNCES FILING OF REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING
ONO PHARMACEUTICAL MAKES ADDITIONAL EQUITY INVESTMENT IN TELIOS
TELIOS PHARMACEUTICALS INC. OFFERS 4.5 MILLION SHARES OF COMMON STOCK
SPARTA PHARMACEUTICALS INC. ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING
ANDRX CORPORATION ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING
TELIOS PHARMACEUTICALS COMPLETES OFFERING OF SECURITIES
TELIOS ANNOUNCES PLANNED TENDER OFFER FOR PREFERRED STOCK AND WARRANTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters